Loading...
OTCM
BCLI
Market cap11mUSD
Jul 09, Last price  
1.07USD
1D
-6.14%
1Q
15.93%
Jan 2017
-97.19%
IPO
-98.52%
Name

Brainstorm Cell Therapeutics Inc

Chart & Performance

D1W1MN
OTCM:BCLI chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
32.64%
Rev. gr., 5y
%
Revenues
0k
0000000000000-366,000000000
Net income
-10m
L
-3,924,485-6,244,000-3,472,000-1,781,000-2,419,000-3,918,000-3,430,000-4,899,000-9,246,000-8,488,000-4,982,000-4,952,000-13,948,000-23,253,000-31,811,000-24,457,000-24,277,000-17,192,00011,623,000-10,307,000
CFO
-7m
L-23.29%
-855,000-1,774,000-1,734,000-744,000-2,069,000-2,223,000-2,916,000-4,054,000-4,487,000-7,408,000-5,858,000-2,364,000-12,388,000-11,247,000-35,193,000-26,265,000-19,320,000-20,458,000-9,093,000-6,975,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform. This platform employs sophisticated cell culture techniques to prompt mesenchymal stem cells, derived from the patient's own bone marrow, to produce high concentrations of neurotrophic factors. This process aims to regulate neuroinflammatory and neurodegenerative disease mechanisms, bolster the survival of neurons, and ultimately enhance neurological function. NurOwn is currently undergoing significant clinical development, having completed a Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS). Additionally, it has successfully advanced through Phase II clinical trials for both progressive multiple sclerosis and Alzheimer's disease, with potential applications being explored for other neurodegenerative conditions. To support its therapeutic pipeline, the company has established a manufacturing partnership with Catalent for NurOwn. Incorporated in 2000, the company initially operated as Golden Hand Resources Inc. before adopting the name Brainstorm Cell Therapeutics Inc. in November 2004. Its corporate headquarters are situated in New York, New York.
URL
https://brainstorm-cell.com/
IPO date
May 28, 2003
Employees
44
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT